| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Clinical Research Centers |
Bone Center and Burns and Allen Research Institute, Cedars-Sinai Medical Center, University of California School of Medicine (J.S.A., V.K., C.W., M.J.), Los Angeles, California 90048; and the Department of Pediatrics, Medical University of South Carolina (B.W.H.), Charleston, South Carolina 29425
Address all correspondence and requests for reprints to: John S. Adams, M.D., B131, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048. E-mail: adamsj{at}cshs.org
| Abstract |
|---|
|
|
|---|
14 ng/mL). Twelve of these subjects harbored a low 25OHD level and
consented to undergo replacement with 50,000 IU vitamin D2
twice weekly for 5 weeks. Five hundred thousand units of oral vitamin
D2 resulted in significant increases in 25OHD (+24.3
± 16.9 ng/mL; P < 0.001) and the fasting urinary
calcium/creatinine excretion ratio (+0.06 ± 0.004;
P = 0.01) and significant decreases in the serum
concentration of PTH (-32.9 ± 36.9 pg/mL; P
< 0.001) and osteocalcin (-4.9 ± 2.4 ng/mL;
P < 0.001). Vitamin D repletion was associated
with a significant 45% annualized increase in bone mineral density
at both the lumbar spine (P < 0.001) and the
femoral neck (P = 0.03), indicating that resolution
of vitamin D insufficiency in a population of patients with low bone
mass results in a rapid rebound increase in bone mineral density. | Introduction |
|---|
|
|
|---|
| Subjects and Methods |
|---|
|
|
|---|
2 h), fasting urine sample for
calcium and creatinine determinations. Serum 25OHD was determined by
competitive protein binding assay (Endocrine Sciences, Inc., Woodland Hills, CA). Serum iPTH and TSH levels were
determined in immunoradiometric assays (Nichols Institute Diagnostics, San Juan Capistrano, CA). Calcium, albumin, and
creatinine were determined spectrophotometrically. The bone mineral
densities of the lumbar spine and nondominant proximal femur were
assessed by dual energy x-ray absorptiometry (Lunar Corp.,
Madison, WI); in all subjects, bone mineral density was greater than
-1.50 SD. below peak bone mass at the hip, spine, or both,
compatible with the diagnosis of osteopenia or osteoporosis (6).
Eighteen patients, 16 women and 2 men (mean age, 60 ± 18 yr), had
a serum 25OHD level of 14 ng/mL (
35 nmol/L) or less. Two patients
were hypercalcemic, with an elevated iPTH level compatible with the
diagnosis of primary hyperparathyroidism. Four additional subjects had
an abnormal TSH level in accord with hyperthyroidism (n = 2) or
hypothyroidism (n = 2). Because these confounding endocrine
disturbances may independently affect skeletal homeostasis, only 12
subjects with a low 25OHD level underwent a therapeutic course of oral
vitamin D2 (50,000 IU, twice weekly) for 5 weeks. The diet
of all patients was supplemented with 1000 mg elemental calcium in the
form of calcium carbonate on a daily basis and was maintained for the
duration of observation. Their serum levels of 25OHD and iPTH, urinary
calcium/creatinine ratio, and bone mineral density were measured a
second time, at a mean of 10 months after completion of treatment. No
other pharmacological intervention was made during this period.
All data are expressed as the mean ± SD. Statistical comparisons were made using Wilcoxons rank sum test.
| Results and Discussion |
|---|
|
|
|---|
|
Although vitamin D supplementation is recognized as an effective adjunct to sunlight exposure and is useful in prevention of vitamin D deficiency (11), little is known about the skeletal response to the reversal of the condition. Chapuy et al. (12) showed a 1.9% annualized increase in femoral neck density in French nursing home residents randomized to 800 IU vitamin D3 and calcium supplementation on a daily basis; however, in this study, patients with 25OHD levels of 35 nmol/L or 14 ng/mL or less were not identified and evaluated independently of vitamin-replete subjects in terms of bone mineral density. In the current study, all 12 vitamin D-depleted subjects experienced an increase in bone mineral density within months of initiating therapy. The mean increase in bone mineral density at the lumbar spine (4.1%) and femoral neck (4.9%) was 2- to 3-fold greater than the annualized increase in bone mineral density observed by Chapuy et al. (12) in subjects receiving roughly the same cumulative dose of vitamin D (438,000 IU) over 78 weeks that our patients received (500,000 IU) in just 5 weeks.
The increase in bone mineral density observed in our patients was most
likely due to resolution or improvement of secondary
hyperparathyroidism with a subsequent decrease in bone turnover (1)
(Table 1
). Although we have followed our treated subjects for only an
average of 10 months after treatment, we predict that the gains in bone
mineral density will follow the pattern of gains observed in patients
successfully treated for primary hyperparathyroidism (1). In
conclusion, we confirm earlier observations (10) that the presence of
vitamin D insufficiency may be a common occurrence in
osteopenic/osteoporotic patient populations even in sunlight-enriched,
lower latitude environments and demonstrate that return to normal
vitamin D balance can result in a prompt and substantial increase in
bone mineral density.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received March 18, 1999.
Revised April 28, 1999.
Accepted May 4, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. A. Bowden, R. F. Robinson, R. Carr, and J. D. Mahan Prevalence of Vitamin D Deficiency and Insufficiency in Children With Osteopenia or Osteoporosis Referred to a Pediatric Metabolic Bone Clinic Pediatrics, June 1, 2008; 121(6): e1585 - e1590. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Holick, R. M. Biancuzzo, T. C. Chen, E. K. Klein, A. Young, D. Bibuld, R. Reitz, W. Salameh, A. Ameri, and A. D. Tannenbaum Vitamin D2 Is as Effective as Vitamin D3 in Maintaining Circulating Concentrations of 25-Hydroxyvitamin D J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 677 - 681. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Boonen, P. Lips, R. Bouillon, H. A. Bischoff-Ferrari, D. Vanderschueren, and P. Haentjens Need for Additional Calcium to Reduce the Risk of Hip Fracture with Vitamin D Supplementation: Evidence from a Comparative Metaanalysis of Randomized Controlled Trials J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1415 - 1423. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Chien and P. E. Goss Aromatase Inhibitors and Bone Health in Women With Breast Cancer J. Clin. Oncol., November 20, 2006; 24(33): 5305 - 5312. [Full Text] [PDF] |
||||
![]() |
D. M. Antoniucci, E. Vittinghoff, T. Blackwell, D. M. Black, and D. E. Sellmeyer Vitamin D Insufficiency Does Not Affect Bone Mineral Density Response to Raloxifene J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4566 - 4572. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Boyle, M. L. Noschese, S. L. Watts, M. E. Davis, S. E. Stenner, and N. Lechtzin Failure of High-Dose Ergocalciferol to Correct Vitamin D Deficiency in Adults with Cystic Fibrosis Am. J. Respir. Crit. Care Med., July 15, 2005; 172(2): 212 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Antoniucci, D. M. Black, and D. E. Sellmeyer Serum 25-Hydroxyvitamin D Is Unaffected by Multiple Freeze-Thaw Cycles Clin. Chem., January 1, 2005; 51(1): 258 - 261. [Full Text] [PDF] |
||||
![]() |
L. Cooper, P. B Clifton-Bligh, M L. Nery, G. Figtree, S. Twigg, E. Hibbert, and B. G Robinson Vitamin D supplementation and bone mineral density in early postmenopausal women Am. J. Clinical Nutrition, May 1, 2003; 77(5): 1324 - 1329. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lips Vitamin D Deficiency and Secondary Hyperparathyroidism in the Elderly: Consequences for Bone Loss and Fractures and Therapeutic Implications Endocr. Rev., August 1, 2001; 22(4): 477 - 501. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Kantorovich, M. A. Gacad, L. L. Seeger, and J. S. Adams Bone Mineral Density Increases with Vitamin D Repletion in Patients with Coexistent Vitamin D Insufficiency and Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3541 - 3543. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |